Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Fricke, A ^a   Ullrich, P V ^a   Cimniak, A F V ^a   Becherer, C ^a   Follo, M ^a   Heinz, J ^a   Scholber, J ^b   Herget, G W ^a   Hauschild, O ^a   Wittel, U A ^a   Stark, G B ^a   Bannasch, H ^a   Braig, D ^a   Eisenhardt, S U ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Biomarker; FACS; Microvesicles; Sarcoma

Indexed keywords

ANTIGEN; BETA3 INTEGRIN; CD142 ANTIGEN; CD45 ANTIGEN; CD62E ANTIGEN; CD63 ANTIGEN; HEMOGLOBIN; LIPOCORTIN 5; PADGEM PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACTIVATED PLATELET DERIVED MICROVESICLE; ADULT; ARTICLE; CANCER GRADING; CANCER SURGERY; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATOFIBROSARCOMA PROTUBERANS; EXTRASKELETAL MYXOID CHONDROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; LEUKOCYTE COUNT; LIPOSARCOMA; MEDICAL HISTORY; MEMBRANE MICROPARTICLE; MYOFIBROBLASTIC SARCOMA; MYXOID FIBROSARCOMA; MYXOID MALIGNANT FIBROUS HISTIOCYTOMA; PLEOMORPHIC SARCOMA; PROTEIN BLOOD LEVEL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM; AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; FLOW CYTOMETRY; LEUKOCYTE; METABOLISM; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RISK; SARCOMA; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; AGED; ANNEXIN A5; BIOMARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; MIDDLE AGED; PLATELET ACTIVATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RISK; SARCOMA; VENOUS THROMBOEMBOLISM;

EID: 85027115139     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3515-y     Document Type: Article

References (34)

1. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107:1047-57.
2. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Onc Hem. 1999;30:111-42.
3. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101:439-51.
4. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123:8-23.
5. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;177:536-43.
6. Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007;137:36-48.
7. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006;52:657-64.
8. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694.
9. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752-60.
10. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer. 2003;39:184-91.
11. Setzer F, Oberle V, Blass M, Moller E, Russwurm S, Deigner HP, et al. Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets. 2006;17:571-6.
12. Majka M, Kijowski J, Lesko E, Gozdizk J, Zupanska B, Ratajczak MZ. Evidence that platelet-derived microvesicles may transfer platelet-specific immunoreactive antigens to the surface of endothelial cells and CD34+ hematopoietic stem/ progenitor cells--implication for the pathogenesis of immune thrombocytopenias. Folia Histochem Cytobiol. 2007;45:27-32.
13. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604-11.
14. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest. 1997;99:2118-27.
15. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008;100:663-9.
16. Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol. 2001;38:2-5.
17. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6:1517-24.
18. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15:6830-40.
19. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-35.
20. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-64.
21. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27:4839-47.
22. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol. 2007;25:1519-24.
23. Jayachandran M, Miller VM, Heit JA, Owen WG. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods. 2012;375:207-14.
24. Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, et al. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res. 2008;28:1107-12.
25. Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichle S, Mourey G, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol. 2014;134:176-82.
26. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, et al. CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res. 2010;30:1707-12.
27. Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichle S, Mourey G, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol. 2013;134:176-82.
28. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108:139-45.
29. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001;12:43-50.
30. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007;97:119-23.
31. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17-21.
32. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53.
33. Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;epub ahead of print.
34. Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;epub ahead of print.